Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eczema drug combo enters early human testing

NCT ID NCT07027527

Ongoing Disease control Sponsor: Apogee Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a combination of two experimental drugs, APG777 and APG990, in 86 adults with moderate-to-severe atopic dermatitis (eczema). The main goal is to check safety and how the drugs move through the body, comparing them to the existing treatment Dupixent. Participants will receive injections over 24 weeks and be followed for about 82 weeks total.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
APG777 and APG990 (injectable drugs)
What this could lead to
If successful, this could lead to a new treatment option for people with moderate-to-severe eczema that may work differently than current therapies.
What could go wrong
This is an early Phase 1b study focused on safety and drug levels, not yet on effectiveness. The combination may not prove better or safer than existing treatments like Dupixent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

  • Investigational Site

    Darlinghurst, New South Wales, 2010, Australia

  • Investigational Site

    Kogarah, New South Wales, 2217, Australia

  • Investigational Site

    Westmead, New South Wales, 2145, Australia

  • Investigational Site

    Woolloongabba, Queensland, 4102, Australia

  • Investigational Site

    Carlton, Victoria, 3053, Australia

  • Investigational Site

    East Melbourne, Victoria, 3002, Australia

  • Investigational Site

    Mitcham, Victoria, 3132, Australia

  • Investigational Site

    Parkville, Victoria, 3050, Australia

  • Investigational Site

    Fremantle, Western Australia, 6160, Australia

  • Investigational Site

    London, Ontario, N6H 5L5, Canada

  • Investigational Site

    Peterborough, Ontario, K9J 5K2, Canada

  • Investigational Site

    Richmond Hill, Ontario, L4B 1A5, Canada

  • Investigational Site

    Toronto, Ontario, M4E 1R7, Canada

  • Investigational Site

    Toronto, Ontario, M4W 2N4, Canada

  • Investigational Site

    Toronto, Ontario, M5A 3R6, Canada

  • Investigational Site

    Montreal, Quebec, H1Y 3L1, Canada

  • Investigational Site

    Québec, Quebec, G1W 1S2, Canada

  • Investigational Site

    Sherbrooke, Quebec, J1G 1X9, Canada

  • Investigational Site

    Hamilton, Waitako, 3204, New Zealand

  • Investigational Site

    Auckland, 1051, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.